KWM
SMMT icon

Kingsview Wealth Management’s Summit Therapeutics SMMT Stock Holding History

Kingsview Wealth Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-46,337
Closed -$894K – 1215
2025
Q1 		$894K Buy
+46,337
New +$930K 0.02% 578

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Kingsview Wealth Management's SMMT Position: Q2 2025 in Review

Kingsview Wealth Management sold out of Summit Therapeutics (SMMT) in Q2 2025, closing a stake of 46,337 shares — an estimated $894K sold.

Kingsview Wealth Management first reported a position in SMMT in Q1 2025 and held it in 1 quarter. The position peaked at $894K in Q1 2025. 238 funds tracked by Wall St. Rank hold SMMT as of Q2 2025.

  • Kingsview Wealth Management reported no remaining Summit Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Kingsview Wealth Management sold 46,337 Summit Therapeutics shares in Q2 2025, an estimated $894K.
  • Kingsview Wealth Management first reported a position in Summit Therapeutics in Q1 2025 and held it in 1 quarter.
  • Kingsview Wealth Management's Summit Therapeutics position peaked at $894K in Q1 2025.
  • 238 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2025.

Based on Kingsview Wealth Management's 13F filing for Q2 2025, filed 8 Aug 2025.